189 related articles for article (PubMed ID: 23248265)
1. The key role of IL-6-arginase cascade for inducing dendritic cell-dependent CD4(+) T cell dysfunction in tumor-bearing mice.
Narita Y; Kitamura H; Wakita D; Sumida K; Masuko K; Terada S; Nakano K; Nishimura T
J Immunol; 2013 Jan; 190(2):812-20. PubMed ID: 23248265
[TBL] [Abstract][Full Text] [Related]
2. Antitumour activity mediated by CD4+ cytotoxic T lymphocytes against MHC class II-negative mouse hepatocellular carcinoma induced by dendritic cell vaccine and interleukin-12.
Homma S; Komita H; Sagawa Y; Ohno T; Toda G
Immunology; 2005 Aug; 115(4):451-61. PubMed ID: 16011514
[TBL] [Abstract][Full Text] [Related]
3. Tumor-educated CD11bhighIalow regulatory dendritic cells suppress T cell response through arginase I.
Liu Q; Zhang C; Sun A; Zheng Y; Wang L; Cao X
J Immunol; 2009 May; 182(10):6207-16. PubMed ID: 19414774
[TBL] [Abstract][Full Text] [Related]
4. IL-6-STAT3 controls intracellular MHC class II alphabeta dimer level through cathepsin S activity in dendritic cells.
Kitamura H; Kamon H; Sawa S; Park SJ; Katunuma N; Ishihara K; Murakami M; Hirano T
Immunity; 2005 Nov; 23(5):491-502. PubMed ID: 16286017
[TBL] [Abstract][Full Text] [Related]
5. Adenovirus vector-mediated overexpression of a truncated form of the p65 nuclear factor kappa B cDNA in dendritic cells enhances their function resulting in immune-mediated suppression of preexisting murine tumors.
Lee JM; Mahtabifard A; Yamada R; Crystal RG; Korst RJ
Clin Cancer Res; 2002 Nov; 8(11):3561-9. PubMed ID: 12429647
[TBL] [Abstract][Full Text] [Related]
6. IL-6 down-regulates HLA class II expression and IL-12 production of human dendritic cells to impair activation of antigen-specific CD4(+) T cells.
Ohno Y; Kitamura H; Takahashi N; Ohtake J; Kaneumi S; Sumida K; Homma S; Kawamura H; Minagawa N; Shibasaki S; Taketomi A
Cancer Immunol Immunother; 2016 Feb; 65(2):193-204. PubMed ID: 26759006
[TBL] [Abstract][Full Text] [Related]
7. Impaired ability of MHC class II-/- dendritic cells to provide tumor protection is rescued by CD40 ligation.
Hermans IF; Ritchie DS; Daish A; Yang J; Kehry MR; Ronchese F
J Immunol; 1999 Jul; 163(1):77-81. PubMed ID: 10384102
[TBL] [Abstract][Full Text] [Related]
8. Tumor-mediated down-regulation of MHC class II in DC development is attributable to the epigenetic control of the CIITA type I promoter.
Choi YE; Yu HN; Yoon CH; Bae YS
Eur J Immunol; 2009 Mar; 39(3):858-68. PubMed ID: 19224634
[TBL] [Abstract][Full Text] [Related]
9. Active CD4+ helper T cells directly stimulate CD8+ cytotoxic T lymphocyte responses in wild-type and MHC II gene knockout C57BL/6 mice and transgenic RIP-mOVA mice expressing islet beta-cell ovalbumin antigen leading to diabetes.
Ye Z; Ahmed KA; Hao S; Zhang X; Xie Y; Munegowda MA; Meng Q; Chibbar R; Xiang J
Autoimmunity; 2008 Nov; 41(7):501-11. PubMed ID: 18855194
[TBL] [Abstract][Full Text] [Related]
10. Tumor-induced interleukin 10 suppresses the ability of splenic dendritic cells to stimulate CD4 and CD8 T-cell responses.
Yang AS; Lattime EC
Cancer Res; 2003 May; 63(9):2150-7. PubMed ID: 12727833
[TBL] [Abstract][Full Text] [Related]
11. DC-induced CD8(+) T-cell response is inhibited by MHC class II-dependent DX5(+)CD4(+) Treg.
Han WG; Schuurhuis DH; Fu N; Camps M; van Duivenvoorde LM; Louis-Plence P; Franken KL; Huizinga TW; Melief CJ; Toes RE; Ossendorp F
Eur J Immunol; 2009 Jul; 39(7):1765-73. PubMed ID: 19544486
[TBL] [Abstract][Full Text] [Related]
12. Switching from a restricted to an effective CD4 T cell response by activating CD8+ murine dendritic cells with a Toll-like receptor 9 ligand.
Rizzitelli A; Vremec D; Villadangos JA; Mavaddat N; Wright MD; Shortman K
Eur J Immunol; 2005 Nov; 35(11):3209-20. PubMed ID: 16224811
[TBL] [Abstract][Full Text] [Related]
13. Neuropeptide signaling activates dendritic cell-mediated type 1 immune responses through neurokinin-2 receptor.
Kitamura H; Kobayashi M; Wakita D; Nishimura T
J Immunol; 2012 May; 188(9):4200-8. PubMed ID: 22474018
[TBL] [Abstract][Full Text] [Related]
14. Dual role of dendritic cells in the induction and down-regulation of antigen-specific cutaneous inflammation.
Krasteva M; Kehren J; Horand F; Akiba H; Choquet G; Ducluzeau MT; Tédone R; Garrigue JL; Kaiserlian D; Nicolas JF
J Immunol; 1998 Feb; 160(3):1181-90. PubMed ID: 9570532
[TBL] [Abstract][Full Text] [Related]
15. Melanoma cell necrosis facilitates transfer of specific sets of antigens onto MHC class II molecules of dendritic cells.
Röhn TA; Schadendorf D; Sun Y; Nguyen XD; Roeder D; Langen H; Vogt AB; Kropshofer H
Eur J Immunol; 2005 Oct; 35(10):2826-39. PubMed ID: 16163671
[TBL] [Abstract][Full Text] [Related]
16. Peptides corresponding to CD4-interacting regions of murine MHC class II molecules modulate immune responses of CD4+ T lymphocytes in vitro and in vivo.
Shen X; Hu B; McPhie P; Wu X; Fox A; Germain RN; König R
J Immunol; 1996 Jul; 157(1):87-100. PubMed ID: 8683160
[TBL] [Abstract][Full Text] [Related]
17. Dendritic cells recruit T cell exosomes via exosomal LFA-1 leading to inhibition of CD8+ CTL responses through downregulation of peptide/MHC class I and Fas ligand-mediated cytotoxicity.
Xie Y; Zhang H; Li W; Deng Y; Munegowda MA; Chibbar R; Qureshi M; Xiang J
J Immunol; 2010 Nov; 185(9):5268-78. PubMed ID: 20881190
[TBL] [Abstract][Full Text] [Related]
18. IL-12 is both required and sufficient for initiating T cell reactivity to a class I-restricted tumor peptide (P815AB) following transfer of P815AB-pulsed dendritic cells.
Bianchi R; Grohmann U; Belladonna ML; Silla S; Fallarino F; Ayroldi E; Fioretti MC; Puccetti P
J Immunol; 1996 Aug; 157(4):1589-97. PubMed ID: 8759743
[TBL] [Abstract][Full Text] [Related]
19. Alternative metabolic states in murine macrophages reflected by the nitric oxide synthase/arginase balance: competitive regulation by CD4+ T cells correlates with Th1/Th2 phenotype.
Munder M; Eichmann K; Modolell M
J Immunol; 1998 Jun; 160(11):5347-54. PubMed ID: 9605134
[TBL] [Abstract][Full Text] [Related]
20. Differential responses of invariant V alpha 24J alpha Q T cells and MHC class II-restricted CD4+ T cells to dexamethasone.
Milner JD; Kent SC; Ashley TA; Wilson SB; Strominger JL; Hafler DA
J Immunol; 1999 Sep; 163(5):2522-9. PubMed ID: 10452989
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
